scholarly journals Improvement in Food Intolerance Symptoms after Pretreatment with Antibiotics Followed by Faecal Microbiota Transplantation: A Case Report

2021 ◽  
pp. 7-13
Author(s):  
Annabel Clancy ◽  
Thomas Borody
Keyword(s):  
Abdominal Pain ◽  
Effective Treatment ◽  
Energy Levels ◽  
Faecal Microbiota ◽  
Dairy Foods ◽  
Faecal Microbiota Transplantation ◽  
Bowel Habits ◽  
Patient Reported ◽  
History Of ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a chronic gastrointestinal condition characterized by abdominal pain and altered bowel habits. Non-immune food reactions or food intolerances affect up to 20% of the general population and are commonly seen in patients with IBS. Faecal microbiota transplantation (FMT) has been described as an emerging, effective treatment for IBS. To date, there have been no reports on changes in food intolerances in patients with IBS treated with FMT. A 35-year-old female presented with an 18-month history of nausea, abdominal pain, alternating bowel habits, headaches/migraines, brain fog, and fatigue. The patient described severe food intolerances to dairy, gluten, egg, and soy. Extensive investigation identified no pathology, and IBS was diagnosed. The patient underwent treatment with antibiotics followed by treatment with FMT enema infusions decreasing in frequency for 12 months. At 12-week follow-up during FMT infusions, the patient reported an 80–90% improvement in her symptoms with formed bowel motions 1–2/day, occasional abdominal pain, and nausea and improved energy levels. The patient reported progressive improvements in her food tolerance from approximately 2 months into the FMT treatment. At week 24, she was tolerating gluten and dairy foods in her diet. At week 52, she was including gluten and dairy in her diet with no symptoms. This case demonstrates that antibiotics, followed by FMT may be an effective treatment for IBS and food intolerances pointing to the gut microbiome as a potential target for treatment.

scholarly journals Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e048541
Author(s):  
Anna-Maria Hoffmann-Vold ◽  
Håvard H Fretheim ◽  
Vikas K Sarna ◽  
Imon Barua ◽  
Maylen N Carstens ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Pilot Study ◽  
Phase Ii ◽  
Intestinal Microbiome ◽  
Induction Phase ◽  
Inflammatory Disorder ◽  
Faecal Microbiota ◽  
Safety And Efficacy ◽  
Faecal Microbiota Transplantation ◽  
Patient Reported

IntroductionIn the multisystem inflammatory disorder systemic sclerosis (SSc), gastrointestinal tract (GIT) affliction is highly prevalent. There are no known disease modifying therapies and the negative impact is substantial. Aiming for a new therapeutic principle, and inspired by recent work showing associations between gut microbiota changes and GIT symptoms in SSc, we performed a pilot study on faecal microbiota transplantation (FMT) with the single-donor bacterial culture ‘Anaerobic Cultivated Human Intestinal Microbiome (ACHIM)’. Motivated by positive pilot study signals, we designed the ReSScue trial as a phase II multicentre, placebo-controlled, randomised 20-week trial to evaluate safety and efficacy on lower GIT symptoms of FMT by ACHIM in SSc.Methods and analysesWe aim to include 70 SSc participants with moderate to severe lower GIT symptoms, defined by the validated patient-reported University of California Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 2.0 questionnaire. The trial includes three parts. In part A1 (induction phase) lasting from week 0 to week 12, participants will be randomised 1:1 to repeat infusions of 30 mL ACHIM or placebo at week 0 and 2 by gastroduodenoscopy. In part A2, which is an 8-week subsequent maintenance phase, all study participants will receive 30 mL ACHIM at week 12 and followed until week 20 on continued blind. In part B, which will last until the last participant completes part A2, the participants will be followed through a maximum 16-week extended monitoring period, for longer-term data on safety and intervention effects. Primary endpoint is change from baseline to week 12 in UCLA GIT subscale scores of diarrhoea or bloating, depending on the worst symptom at baseline evaluated separately for each patient. Secondary endpoints are safety measures and changes in UCLA GIT scores (total, diarrhoea and bloating).Ethics and disseminationThis protocol was approved by the Northern Norwegian Committee for Medical Ethics. Study findings will be published.Trial registration numberNCT04300426; Pre-results.Protocol versionV.3.1.

scholarly journals Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study

Gut ◽  
2019 ◽  
Vol 69 (5) ◽  
pp. 859-867 ◽  
Author(s):  
Magdy El-Salhy ◽  
Jan Gunnar Hatlebakk ◽  
Odd Helge Gilja ◽  
Anja Bråthen Kristoffersen ◽  
Trygve Hausken
Keyword(s):  
Irritable Bowel Syndrome ◽  
Secondary Outcome ◽  
Controlled Study ◽  
Rrna Gene ◽  
Faecal Microbiota ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Faecal Microbiota Transplantation ◽  
Link Type ◽  
Irritable Bowel

ObjectiveFaecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings.DesignThis randomised, double-blind, placebo-controlled study randomised 165 patients with IBS to placebo (own faeces), 30 g FMT or 60 g FMT at a ratio of 1:1:1. The material for FMT was obtained from one healthy, well-characterised donor, frozen and administered via gastroscope. The primary outcome was a reduction in the IBS symptoms at 3 months after FMT (response). A response was defined as a decrease of 50 or more points in the total IBS symptom score. The secondary outcome was a reduction in the dysbiosis index (DI) and a change in the intestinal bacterial profile, analysed by 16S rRNA gene sequencing, at 1 month following FMT.ResultsResponses occurred in 23.6%, 76.9% (p<0.0001) and 89.1% (p<00.0001) of the patients who received placebo, 30 g FMT and 60 g FMT, respectively. These were accompanied by significant improvements in fatigue and the quality of life in patients who received FMT. The intestinal bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms.ConclusionsFMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose.Trial registrationwww.clinicaltrials.gov (NCT03822299) and www.cristin.no (ID657402).

scholarly journals Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply

2020 ◽  
Vol 52 (3) ◽  
pp. 557-558
Author(s):  
Perttu Lahtinen ◽  
Jonna Jalanka ◽  
Anna Hartikainen ◽  
Eero Mattila ◽  
Markku Hillilä ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Irritable Bowel

600 Multi Donor Intense Faecal Microbiota Transplantation is an Effective Treatment for Resistant Ulcerative Colitis: A Randomised Placebo-Controlled Trial

2016 ◽  
Vol 150 (4) ◽  
pp. S122-S123 ◽  
Author(s):  
Sudarshan Paramsothy ◽  
Michael A. Kamm ◽  
Alissa Walsh ◽  
Johan van den Bogaerde ◽  
Douglas Samuel ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Effective Treatment ◽  
Controlled Trial ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation

No benefit of faecal microbiota transplantation for IBS-D

2020 ◽  
Vol 58 (6) ◽  
pp. 87-87
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Faecal Microbiota ◽  
Double Blind ◽  
Faecal Microbiota Transplantation ◽  
Irritable Bowel

AbstractReview of: Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2019;4:675–85.

Sign in / Sign up

Export Citation Format

Share Document